In the current study, among this 6-lncRNA signature, NAV2-AS2, STEAP3-AS1 and GLIS3-AS1 are antisense lncRNAs, and there is growing evidence that a large number of antisense lncRNAs play crucial roles in cancer 39-40. This evidence concerns the gene NAV2 and cancer.